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Idiopathic  pulmonary  arterial  hypertension  (IPAH)  is characterized  by  pulmonary  vascular  remodeling.
We  have  reported  that high-dose  prostaglandin  I2 (PGI2)  therapy  markedly  improved  hemodynamics  in
IPAH  patients  and  that PGI2 induced  apoptosis  of pulmonary  artery  smooth  muscle  cells obtained  from
IPAH  patients.  PGI2 is thought  to  have  reverse  remodeling  effects,  although  it has  not been histologically
conﬁrmed.  In a case  series,  we examined  the  reverse  pulmonary  vascular  remodeling  effects  of  PGI2 in
lung  tissues  obtained  from  an  IPAH  patient  treated  with  high-dose  PGI2 and  an  IPAH patient  not  treated
with  PGI2. Apoptotic  cells  were  detected  in small  pulmonary  arteries  of the  IPAH  patient  treated  with  high-
dose  PGI2 but  not  in  those  from  the IPAH  patient  not  treated  with  PGI2. Media  of  peripheral  pulmonary
arteries  were  thick  in  the  IPAH  patient  not  treated  with  PGI2. On  the  other  hand,  media  of peripheral
pulmonary  arteries  were  thin in the  IPAH  patient  treated  with  high-dose  PGI2. The  single  case  reportdiopathic  pulmonary arterial hypertension suggested  that  high-dose  PGI2 therapy  has  the  potential  for  reverse  pulmonary  vascular  remodeling  by
induction  of apoptosis  and  reduction  of medial  hypertrophy.  Accumulation  of  cases  is  needed  for  the
application  to generalized  effect  of  high-dose  PGI2.
<Learning  objective:  Reverse  pulmonary  vascular  remodeling  would  provide  further  improvement  in
patients  with  IPAH.  High-dose  PGI2 therapy  has  the  potential  for  reverse  pulmonary  vascular  remodeling
in  patients  with  IPAH.>
©  2014  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ntroductionIdiopathic pulmonary arterial hypertension (IPAH) is charac-
erized by vasoconstriction and vascular remodeling of pulmonary
rteries [1]. Reverse remodeling as well as vasodilatation of
ulmonary arteries would be desirable in patients with IPAH. We
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878-5409/$ – see front matter © 2014 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jccase.2013.12.011have reported that high-dose intravenous prostaglandin I2 (PGI2)
therapy (>40 ng/kg/min) resulted in marked reduction in mean
pulmonary artery pressure [2] and that PGI2 induced apoptosis of
cultured pulmonary artery smooth muscle cells (PASMCs) obtained
from patients with IPAH [3]. These results suggest that high-dose
intravenous PGI2 therapy would reverse pulmonary vascular
remodeling by induction of apoptosis in PAH-PASMCs, although it
has not been histologically conﬁrmed. We  experienced a patient
with IPAH who  underwent cadaveric lung transplantation (CLT),
although his clinical condition and hemodynamics were improved
by high-dose intravenous PGI2 monotherapy. We examined the
reverse pulmonary vascular remodeling effects of PGI2 in lung
tissues obtained from patients with IPAH treated with high-dose
PGI2 or not treated with PGI2.
vier Ltd. All rights reserved.
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aterials and methods
Lung  tissues were obtained from two patients with IPAH at
ung transplantation. As controls, lung tissues were obtained at
ung lobectomy from a patient with lung cancer who had no pul-
onary hypertension. All human subject protocols were approved
y the Human Ethics Committee of Okayama University Graduate
chool of Medicine, Dentistry, and Pharmaceutical Sciences, and
ritten informed consent was obtained from all patients before the
rocedure. Terminal deoxynucleotidyl transferase dUTP nick end
abeling (TUNEL) assays were performed on frozen sections with
n ApopTag ﬂuorescein in situ apoptosis detection kit (Chemicon
nternational Inc., Temecula, CA, USA). Nuclear morphology was
xamined by labeling with 4′,6-diamidino-2-phenylindole (DAPI)
0.5 L/mL). For identiﬁcation of SMCs, -smooth muscle actin
ouse monoclonal antibody was used. The primary antibody was
etected with rabbit anti-mouse immunoglobulin TRITC (Dako-
ytomation, Glostrup, Denmark). Tissues were analyzed using a
uorescence microscope (LSM5 EXCITER, Carl Zeiss Microimaging
nc., Oberkochen, Germany and Olympus IX71, Olympus Optical Co.
td., Tokyo, Japan). Morphometric analysis was performed on Elas-
ica van Gieson-stained sections from parafﬁn-embedded blocks by
tandard techniques. Pulmonary arteries of 100–300 m in exter-
al diameter were examined.
esults
A  21-year-old man  whose mother had died from pulmonary
ypertension (PH) was diagnosed with familial PAH at the age of 9
ears and had received intravenous PGI2 therapy from the age of
6 years. PGI2 dose had been gradually increased to 115 ng/kg/min
ver a period of about four years. Although mean pulmonary artery
ressure decreased from 106 mmHg  to 45 mmHg  and symptoms
ere improved, he received CLT because of the appearance of a
onor. In lung tissues obtained from the patient, apoptotic cells
ere detected in pulmonary arteries of his lung (Fig. 1). We also
btained lung tissues from a patient with IPAH who was  not treated
ith PGI2 and from a patient with lung cancer. A 28-year-old
oman was diagnosed with IPAH at the age of 22 years. Mean
ulmonary artery pressure was 60 mmHg  and she had received
ntravenous PGI2 therapy at the age of 25 years. However, the ther-
py was discontinued due to interstitial lung disease induced by
GI2 as previously described [4]. The patient was  treated with an
ndothelin receptor antagonist and phosphodiesterase-5 inhibitor
fter the interstitial lung disease had been cured. However, mean
ig. 1. Pulmonary arteries stained by terminal deoxynucleotidyl transferase dUTP nick en
s  TUNEL-positive. Red is -smooth muscle actin. Blue is 4′ ,6-diamidino-2-phenylindole. gy Cases 9 (2014) 173–176
pulmonary  artery pressure was  59 mmHg  at the age of 27 years and
CLT was performed because of the appearance of a donor. No apop-
totic cells were found in lung tissues obtained from the patient who
had not received PGI2 therapy (Fig. 2A) or in lung tissues obtained
from the non-PAH patient (Fig. 2B). Media of peripheral pulmonary
arteries were thick in a patient with IPAH who had not received PGI2
therapy (Fig. 2C). On the other hand, media of peripheral pulmonary
arteries were thin in a patient with IPAH treated with high-dose
PGI2 (Fig. 3) and a non-PAH patient (Fig. 2D).
Discussion
The pulmonary vasculature has been analyzed in almost all
cases by autopsy in patients who  died from progression of PH, and
there have been few studies in which the pulmonary vasculature
in patients whose clinical condition and hemodynamics improved
was analyzed. In the present study, we  analyzed the pulmonary
vasculature in patients who  received high-dose PGI2 therapy and
whose clinical condition and hemodynamics improved. It was his-
tologically conﬁrmed that pulmonary vascular remodeling was
reversible in patients with IPAH. Two case reports have shown that
reduction in pulmonary ﬂow caused a change in pulmonary vascu-
lature in native lungs of patients with IPAH who had undergone
single-lung transplantation [5,6]. Recently, pathological features
of PAH patients treated with current medications were reported
[7]. No signiﬁcant differences were detected in medial thickness
between patients with IPAH and controls. Thus, current medica-
tions for PAH have the potential for reversal of medial hypertrophy.
In this study, improvement of hemodynamics, presence of apop-
totic cells, and less medial hypertrophy were observed in a patient
who received high-dose PGI2 therapy. These results suggest that
high-dose PGI2 has the potential for reverse pulmonary vascular
remodeling by reduction of medial hypertrophy. On the other hand,
increased intimal thickness was  observed in patients treated with
currently recommended medications [7]. Reverse intimal hyper-
trophy will be a target for therapy of PAH in the future.
We  previously reported that PGI2 at a high concentration
(1.0 ng/mL) signiﬁcantly induced apoptosis of cultured pulmonary
artery SMCs obtained from patients with IPAH. However, PGI2
at a low concentration (0.5 ng/mL) did not signiﬁcantly induce
apoptosis [3]. The dose of PGI2 at a high concentration ﬁtted to
100 ng/kg/min PGI2 in clinical settings by calculation from circu-
lating blood volume of 50 kg body weight in humans. Thus, we
consider that reverse remodeling of the pulmonary arteries would
be a direct effect of high-dose PGI2.
d labeling (TUNEL) assay in a patient treated with high-dose prostaglandin I2. Green
Bar = 100 m.  Arrows indicated TUNEL-positive cells.
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Fig. 2. Pulmonary arteries stained by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay and Elastica van Gieson staining in a patient not treated
with  prostaglandin I2 (PGI2) and in a non-pulmonary arterial hypertension (PAH) patient. Upper panel: TUNEL assay. Lower panel: Elastica van Gieson staining. (A and C) A
28-year-old woman who  had not received PGI2 therapy. (B and D) A non-PAH patient.
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edia of peripheral pulmonary arteries were thick.
In this case report, TUNEL-positive cells were stained with anti-
odies against -SMA which are markers for SMC  and media of
eripheral pulmonary arteries were thin in a patient treated with
igh-dose PGI2. We  previously reported that PGI2 at a high con-
entration induced apoptosis of cultured PASMCs obtained from
atients with IPAH [3]. Therefore, TUNEL-positive cells have char-
cteristics of PASMCs.
imitationApoptotic  cells were detected in only one IPAH patient with
igh-dose PGI2 therapy. Accumulation of cases is needed for the
pplication to the generalized effect of high-dose PGI2.
[h high-dose prostaglandin I2. Arrows indicated the peripheral pulmonary arteries.
In conclusion, the single case report suggested that high-dose
PGI2 therapy has the potential for reverse pulmonary vascular
remodeling by induction of apoptosis and reduction of medial
hypertrophy.
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